Krystal Biotech Says KB801 Eye Trial Enrollment Slower Than Expected; Now Sees Topline Data In 2027
Share
Why It Matters
Krystal Biotech's eye medicine study is enrolling patients slower than planned. When watching this stock, slow progress can mean delays in proving a medicine works.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.